Skip to main content
SpringerLink
Log in

Prevention and Management of Osteoporosis

Current Trends and Future Prospects

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

There has been significant progress in the management of osteoporosis in recent years, resulting in a greater choice of therapeutic interventions for the physician. Nearly all of the treatments currently available are antiresorptive agents, which prevent bone loss and, in some cases, have been shown to reduce fracture risk. Some of these agents appear to have site-specific effects in the skeleton and may therefore not protect against all types of osteoporotic fracture. However, other drugs, such as hormone replacement therapy and possibly bisphosphonates, appear to reduce fracture risk in both the spine and hip.

The optimal timing and duration of therapy for osteoporosis remain to be defined and will differ between agents. There is increasing evidence that the changes in bone mass induced by treatment do not always predict the corresponding changes in fracture rate. Thus, significant reductions in fractures may occur with antiresorptive therapy despite very small changes in bone mass, while large increases in bone mass may be associated with reduced bone strength and unchanged or increased fracture rates. Finally, the demonstration that relatively short term interventions can substantially reduce fracture rates, even in the very elderly in whom bone mass is almost universally low, provides the rationale for a more aggressive approach to treatment in patients with established disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646–50

    Article  Google Scholar 

  2. Cooper C, Melton LJ. Vertebral fractures. How large is the silent epidemic? BMJ 1992; 304: 793–4

    Article  PubMed  CAS  Google Scholar 

  3. Melton LJ, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005–10

    Google Scholar 

  4. Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practice. BMJ 1995; 310: 1507–10

    Article  PubMed  CAS  Google Scholar 

  5. Compston JE. Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects. Reprod Med Rev 1994; 3: 209–24

    Article  Google Scholar 

  6. Lindsay R, Hart DM, Forrest C, et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; II: 1151–3

    Article  Google Scholar 

  7. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24

    PubMed  CAS  Google Scholar 

  8. Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 335: 265–9

    Article  Google Scholar 

  9. Ryde SJS, Bowen-Simpkins K, Bowen Simpkins P, et al. The effect of oestradiol implants on regional and total bone mass: a three-year longitudinal study. Clin Endocrinol 1994; 40: 33–8

    Article  CAS  Google Scholar 

  10. Hutchinson A, Polansky SM, Feinstein AR. Postmenopausal estrogens protect against fractures of the hip and distal radius: a case control study. Lancet 1979; II: 705–9

    Article  Google Scholar 

  11. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N Engl J Med 1980; 303: 1195–8

    Article  PubMed  CAS  Google Scholar 

  12. Paganini-Hill A, Ross RK, Gerkins VR, et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981; 95: 28–31

    PubMed  CAS  Google Scholar 

  13. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317: 1169–74

    Article  PubMed  CAS  Google Scholar 

  14. Posthuma WFM, Westendorp RGJ, Vandenbroucke JPP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994; 308: 1268–9

    Article  PubMed  CAS  Google Scholar 

  15. Quigley MET, Martin PL, Burnier AM, et al. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987; 156: 1516–23

    PubMed  CAS  Google Scholar 

  16. Compston JE. Mechanisms of drug-induced effects on bone. In: Compston JE, editor. Osteoporosis. New perspectives on causes, prevention and treatment. London: Royal College of Physicians of London, 1996: 83–95

    Google Scholar 

  17. Lindsay R, Hart DM, MacClean A, et al. Bone response to termination of oestrogen treatment. Lancet 1978; I: 1325–7

    Article  Google Scholar 

  18. Christiansen C, Christensen MS, McNair PL, et al. Prevention of early postmenopausal bone loss: conducted 2-year study in 315 normal females. Eur J Clin Invest 1980; 10: 273–9

    Article  PubMed  CAS  Google Scholar 

  19. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314–9

    Article  CAS  Google Scholar 

  20. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37

    PubMed  CAS  Google Scholar 

  21. Wolf PH, Madans JH, Finucane FF, et al. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164: 489–94

    PubMed  CAS  Google Scholar 

  22. Falkeborn M, Persson I, Adami H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 821–8

  23. McPherson K. Breast cancer and hormonal supplements in postmenopausal women [editorial]. BMJ 1995; 311: 699–700

    Article  PubMed  CAS  Google Scholar 

  24. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996; 348: 429–32

    Article  PubMed  CAS  Google Scholar 

  25. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and the risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 168: 1473–80

    PubMed  CAS  Google Scholar 

  26. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93

    Article  PubMed  CAS  Google Scholar 

  27. Compston JE. The therapeutic use of bisphosphonates. BMJ 1994; 309: 711–5

    Article  PubMed  CAS  Google Scholar 

  28. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71

    Article  PubMed  CAS  Google Scholar 

  29. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 72–9

    Article  Google Scholar 

  30. Liberman UA, Weiss SR, Bröil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437–43

    Article  PubMed  CAS  Google Scholar 

  31. Harris ST, Watts NB, Jackson RD, et al. The effects of four years of intermittent cyclical etidronate treatment for postmenopausal osteoporosis. Am J Med 1993; 95: 557–66

    Article  PubMed  CAS  Google Scholar 

  32. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracture. Lancet 1996; 348: 1535–41

    Article  PubMed  CAS  Google Scholar 

  33. Boyce BF, Fogelman I, Ralston S, et al. Focal osteomalacia due to low-dose diphosphonate therapy in Paget’s disease. Lancet 1984; I: 821–4

    Article  Google Scholar 

  34. Overgaard K, Riis BJ, Christiansen C, et al. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299: 477–9

    Article  PubMed  CAS  Google Scholar 

  35. Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556–61

    Article  PubMed  CAS  Google Scholar 

  36. Reginster JY, Denis D, Deroisy R, et al. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 1994; 9: 69–73

    Article  PubMed  CAS  Google Scholar 

  37. Burckhardt P, Burnand B. The effect of treatment with calcitonin on vertebral fracture rate in osteoporosis. Osteoporosis Int 1993; 3: 24–30

    Article  CAS  Google Scholar 

  38. Parfitt AM, Gallagher JC, Heaney RP, et al. Vitamin D and bone health in the elderly. Am J Clin Nutr 1982; 36: 1014–31

    PubMed  CAS  Google Scholar 

  39. Compston JE. The role of vitamin D and calcium supplementation in the prevention of osteoporotic fractures in the elderly. Clin Endocrinol 1995; 43: 393–405

    Article  CAS  Google Scholar 

  40. Chapuy MC, Arlot ME, DuBoeuf F, et al. Vitamin D3 and calcium to prevent hip fracture in elderly women. N Engl J Med 1992; 327: 1637–42

    Article  PubMed  CAS  Google Scholar 

  41. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081–2

    Article  PubMed  CAS  Google Scholar 

  42. Heikinhimo RJ, Inkovaara JA, Harju EJ. Annual injection of vitamin D and fracture of aged bones. Calcif Tissue Int 1992; 51: 105–10

    Article  Google Scholar 

  43. Lips P, Graafmans WC, Ooms ME, et al. The effect of vitamin D supplementation on the incidence of hip fracture in elderly people [abstract]. J Bone Miner Res 1994; 9 Suppl.: S148

    Google Scholar 

  44. Aloia JF. Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism 1990; 39: 35–8

    Article  PubMed  CAS  Google Scholar 

  45. Cannigia A, Nuti R, Martini G, et al. Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism 1990; 39: 43–9

    Article  Google Scholar 

  46. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 1990; 113: 649–55

    PubMed  CAS  Google Scholar 

  47. Tilyard MW, Spears GFS, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326: 357–62

    Article  PubMed  CAS  Google Scholar 

  48. Orimo H, Shiraki M, Hayashi Y, et al. Effects of lochydroxyvitamin D3 on lumbar bone density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54: 370–6

    Article  PubMed  CAS  Google Scholar 

  49. Ott SM, Chesnut CH. Calcitriol is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110: 261–74

    Google Scholar 

  50. Johnston CC, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 327: 82–7

    Article  PubMed  Google Scholar 

  51. Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. Calcif Tissue Int 1990; 47: 194–201

    Article  PubMed  CAS  Google Scholar 

  52. Dawson-Hughes B, Dallai GE, Krall EA, et al. A controlled trial of the effects of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990; 323: 878–83

    Article  PubMed  CAS  Google Scholar 

  53. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation and hormone replacement therapy. N Engl J Med 1991; 325: 1189–95

    Article  PubMed  CAS  Google Scholar 

  54. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993; 328: 460–4

    Article  PubMed  CAS  Google Scholar 

  55. Elders PJM, Lips P, Netelenbos JC, et al. Long-term effect of calcium supplementation on bone loss in perimenopausal women. J Bone Miner Res 1994; 9: 963–70

    Article  PubMed  CAS  Google Scholar 

  56. Ferrari S, Rizzoli R, Chevalley T, et al. Vitamin D receptor gene polymorphisms and change in lumbar spine bone mineral density. Lancet 1995; 345: 423–4

    Article  PubMed  CAS  Google Scholar 

  57. Mamelle N, Dusan R, Prost A, et al. Risk benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; II: 361–5

    Article  Google Scholar 

  58. Pak CYC, Sakhaee K, Adams-Huet B, et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final update of a randomised controlled trial. Ann Intern Med 1995; 123: 401–8

    PubMed  CAS  Google Scholar 

  59. Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802–9

    Article  PubMed  CAS  Google Scholar 

  60. Kleerekoper M, Peterson E, Nelson DA, et al. A randomised trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991; 1: 155–62

    Article  PubMed  CAS  Google Scholar 

  61. Kleerekoper M. Fluoride: the verdict is in, but the controversy lingers [editorial]. J Bone Miner Res 1996; 11: 565–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital Level 5, Box 157, Cambridge, CB2 2QQ, England

    Juliet E. Compston

Authors
  1. Juliet E. Compston
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compston, J.E. Prevention and Management of Osteoporosis. Drugs 53, 727–735 (1997). https://doi.org/10.2165/00003495-199753050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199753050-00001

Keywords

Search

Navigation